RATIO-PENTOXIFYLLINE TABLET (EXTENDED-RELEASE)

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PENTOXIFYLLINE

から入手可能:

RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED

ATCコード:

C04AD03

INN（国際名）:

PENTOXIFYLLINE

投薬量:

400MG

医薬品形態:

TABLET (EXTENDED-RELEASE)

構図:

PENTOXIFYLLINE 400MG

投与経路:

ORAL

パッケージ内のユニット:

60/100/500TABS

処方タイプ:

Prescription

治療領域:

HEMORRHEOLOGIC AGENTS

製品概要:

Active ingredient group (AIG) number: 0115837001; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2010-08-02

製品の特徴

PRODUCT MONOGRAPH
Pr
ratio-PENTOXIFYLLINE
(pentoxifylline)
400 mg Sustained-Release Tablets
Vasoactive agent
ratiopharm inc.
17800, rue Lapointe
Mirabel (Québec)
Canada, J7J 1P3
Date of Revision:
September 18, 2009
Submission Control No: 131604
_ _
_ _
_Page 2 of 20_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................. 3
SUMMARY
PRODUCT
INFORMATION........................................................ 3
INDICATIONS
AND
CLINICAL
USE ............................................................. 3
CONTRAINDICATIONS
..................................................................................
3
WARNINGS
AND
PRECAUTIONS
................................................................. 4
ADVERSE
REACTIONS...................................................................................
5
DRUG
INTERACTIONS
...................................................................................
6
DOSAGE
AND
ADMINISTRATION
............................................................... 8
OVERDOSAGE
.................................................................................................
8
ACTION
AND
CLINICAL
PHARMACOLOGY.............................................. 8
STORAGE
AND
STABILITY
...........................................................................
9
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ............................... 9
PART II: SCIENTIFIC INFORMATION
....................................................... 10
PHARMACEUTICAL
INFORMATION.........................................................
10
DETAILED
PHARMACOLOGY
....................................................................
11
TOXICOLOGY
................................................................................................
13
REFERENCES
.................................................................................................
17
PART III: CONSUMER
INFORMATION...................................................... 19
_ _
_ _
_ _
_Page 3 of 20_
P
ratio-PENTOXIFYLLINE
(pentoxifylli